The global qPCR instruments market size accounted for USD 6.8 billion in 2025 and is predicted to increase from USD 7.41 billion in 2026 to approximately USD 15.95 billion by 2035, expanding at a CAGR of 8.9% from 2026 to 2035. The growing infectious diseases, expanding personalized medicines, technological advancements, R&D activities, and government initiatives are promoting the market growth.
The qPCR instruments are the laboratory devices used for amplification and measurement of DNA in real-time. They are being used for the detection of infectious diseases, cancer, and genetic disorders, as well as the detection of pathogens, pollutants, and microbial contaminants in food, water, and soil. They are also used in gene expression analysis, vaccine development, and drug discovery and development.
The growth in infectious disease testing is increasing the demand for qPCR instruments.
Expanding R&D activities are increasing the use of qPCR instruments for biomarker discovery, personalized medicine development, gene expression studies, etc.
Rise in the food safety and environmental monitoring is also increasing their adoption rates.
Growing advancements in point-of-care testing are also increasing the development of portable and miniaturized qPCR devices.
Increasing technological advancements are driving the development of smart qPCR devices with automation, enhancing speed and data management.
The graph represents the estimated cancer cases in the U.S. for the year 2026. It indicates that there will be a rise in cancer deaths and new cases, which will drive the demand for advanced diagnostic solutions. This, in turn, will increase the adoption of qPCR instruments for early and accurate cancer detection, R&D applications, and clinical trials, which will ultimately promote the market growth.
By product type, the instruments segment accounted for the highest revenue share of 42% of the market in 2025, as they are essential for qPCR testing. Their long life span and durability also increased their adoption rates. The presence of advanced features like automation, high throughput, and multiplexing also increased their use for various applications.
By detection method type, the TaqMan probes segment held a major revenue share of 45% of the qPCR instruments market in 2025 and is expected to show the highest growth with a CAGR of 9.5% during the predicted time, due to their high specificity and sensitivity. Their real-time monitoring and reproducibility also increased their demand. The multiplexing capabilities and expanding clinical applications also increased their use.
By throughput type, the medium throughput segment contributed the biggest revenue share of 37% of the qPCR instruments market in 2025, driven by their balanced capacity and affordability. They were also considered ideal for clinical testing and research labs with moderate load samples. Their flexibility also increased their use across research institutes and hospital labs.
By application type, the clinical diagnostics segment held the largest revenue share of 48% of the qPCR instruments market in 2025 and is expected to show the highest growth rate with a CAGR of 9.6% during the upcoming years, due to high demand for infectious disease detection. Their rapid and accurate results also increased their adoption rates across hospitals and labs. Growth in government screening programs and demand for personalized medicine has also increased their use.
By end user, the hospitals & diagnostic centers segment led the qPCR instruments market with 40% in 2025, as they are considered the primary site for disease testing. The high patient volume and government support also increased the adoption of qPCR instruments. The presence of skilled personnel and focus on quality care also increased their acceptance rates.
North America dominated the qPCR instruments market with 38% in 2025, due to the robust healthcare infrastructure, industries, and research institutes. This increased the use of qPCR instruments for early disease detection and R&D activities, where the government funding accelerated their adoption rates. Technological advancements have also increased their innovations and use.
Asia Pacific held 24% share of the qPCR instruments market in 2025 and is expected to expand rapidly with a CAGR of 10.5% during the forecast period, due to expanding healthcare infrastructure and pharmaceutical and biotechnology industries. This is increasing the adoption of qPCR instruments for accurate disease detection and R&D purposes. Growing government support and health awareness are also contributing to the market growth.
Thermo Fisher Scientific held the position of the market leader with its Applied Biosystems brand and QantStudio line, where Bio-Rad Laboratories was its competitor, driven by the high adoption of CFX Opus and CFX Opus Dx. Roche Diagnostics also sustained its position with its LightCycler series, where Danaher contributed to the market growth with the launch of automated molecular diagnostics and the GeneXpert system.
By Product Type
Instruments
Benchtop qPCR Systems
Portable/Compact qPCR Systems
Consumables & Reagents
Assays & Kits
Gene Expression Kits
Pathogen Detection Kits
SNP Genotyping Kits
Master Mixes
Plates & Tubes
Software
Data Analysis Software
Cloud-based Platforms
By Detection Method
SYBR Green
TaqMan Probes
Molecular Beacons
Others (Scorpions, FRET Probes)
By Throughput
Low Throughput
Medium Throughput
High Throughput
By Application
Clinical Diagnostics
Infectious Diseases
Oncology
Genetic Testing
Research Applications
Gene Expression Analysis
Genomics & Proteomics
Forensic Testing
Food & Environmental Testing
By End User
Hospitals & Diagnostic Centers
Academic & Research Institutes
Pharmaceutical & Biotechnology Companies
Contract Research Organizations (CROs)
By Region
North America
U.S.
Canada
Mexico
Rest of North America
Latin America
Brazil
Argentina
Rest of Latin America
Europe
Western Europe
Germany
Italy
France
Netherlands
Spain
Portugal
Belgium
Ireland
UK
Iceland
Switzerland
Poland
Rest of Western Europe
Eastern Europe
Austria
Russia & Belarus
Türkiye
Albania
Rest of Eastern Europe
Asia Pacific
China
Taiwan
India
Japan
Australia and New Zealand
ASEAN Countries (Singapore, Malaysia)
South Korea
Rest of APAC
MEA
GCC Countries
Saudi Arabia
United Arab Emirates (UAE)
Qatar
Kuwait
Oman
Bahrain
South Africa
Egypt
Rest of MEA
